Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

CLL

Katie Kosko
With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.
Kristie L. Kahl
A brief, multimodal psychosocial intervention for caregivers of patients undergoing hematopoietic stem cell transplantation could improve their quality of life, caregiving burden and anxiety and depression symptoms.
Kristie L. Kahl
In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with the associate director of the Information Resource Center at the Leukemia and Lymphoma Society on support groups and other recourses available for those affected by blood cancer.
 
Dr. Matthew Davids
Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.
Kristie L. Kahl
Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.
Jessica Skarzynski
As 2019 comes to a close, take a read through CURE®’s top stories of the year.
Jessica Skarzynski
Take a look back at the top 10 podcasts of 2019 – and be sure to subscribe so you don’t miss an episode in 2020.
Rachelle Berfond
When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.
Tom Castles
Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.
Kristie L. Kahl
The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×